Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Gastrointestinal Cancer
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(3077)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
HER-2 positive
Cholangiocarcinoma
HER-2 positive
Cholangiocarcinoma
BI 1810631
Sensitive: C3 – Early Trials
IASLC-TTLC 2023 - 5 days (New C3)
BI 1810631
Sensitive
:
C3
IASLC-TTLC 2023 - 5d
BI 1810631
Sensitive: C3 – Early Trials
IASLC-TTLC 2023 - 5 days
BI 1810631
Sensitive
:
C3
IASLC-TTLC 2023 - 5 days - (New C3)
HER-2 positive
Esophageal Cancer
HER-2 positive
Esophageal Cancer
BI 1810631
Sensitive: C3 – Early Trials
IASLC-TTLC 2023 - 5 days (New C3)
BI 1810631
Sensitive
:
C3
IASLC-TTLC 2023 - 5d
BI 1810631
Sensitive: C3 – Early Trials
IASLC-TTLC 2023 - 5 days
BI 1810631
Sensitive
:
C3
IASLC-TTLC 2023 - 5 days - (New C3)
HER-2 amplification + RAS wild-type + BRAF wild-type
Colon Cancer
HER-2 amplification + RAS wild-type + BRAF wild-type
Colon Cancer
trastuzumab + tucatinib
Sensitive: A2 - Guideline
NCCN - 1 week (New A2)
trastuzumab + tucatinib
Sensitive
:
A2
NCCN - 1wk
trastuzumab + tucatinib
Sensitive: A2 - Guideline
NCCN - 1 week
trastuzumab + tucatinib
Sensitive
:
A2
NCCN - 1 week - (New A2)
No biomarker
Biliary Tract Cancer
No biomarker
Biliary Tract Cancer
pembrolizumab
Sensitive: B - Late Trials
Merck (MSD) Press Release - 1 week (New B)
pembrolizumab
Sensitive
:
B
Merck (MSD) Press Release - 1wk
pembrolizumab
Sensitive: B - Late Trials
Merck (MSD) Press Release - 1 week
pembrolizumab
Sensitive
:
B
Merck (MSD) Press Release - 1 week - (New B)
HER-2 negative + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
HER-2 negative + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive: A1 - Approval
Pharmabiz - 1 week (New A1)
pembrolizumab
Sensitive
:
A1
Pharmabiz - 1wk
pembrolizumab
Sensitive: A1 - Approval
Pharmabiz - 1 week
pembrolizumab
Sensitive
:
A1
Pharmabiz - 1 week - (New A1)
PD-L1 expression
Esophageal Cancer
PD-L1 expression
Esophageal Cancer
pembrolizumab
Sensitive: A1 - Approval
Pharmabiz - 1 week (New A1)
pembrolizumab
Sensitive
:
A1
Pharmabiz - 1wk
pembrolizumab
Sensitive: A1 - Approval
Pharmabiz - 1 week
pembrolizumab
Sensitive
:
A1
Pharmabiz - 1 week - (New A1)
BRAF V600E
Colorectal Cancer
BRAF V600E
Colorectal Cancer
trametinib + dabrafenib + PDR001
Sensitive: C2 – Inclusion Criteria
Nat Med - 1 week (New C3)
trametinib + dabrafenib + PDR001
Sensitive
:
C2
Nat Med - 1wk
trametinib + dabrafenib + PDR001
Sensitive: C2 – Inclusion Criteria
Nat Med - 1 week
trametinib + dabrafenib + PDR001
Sensitive
:
C2
Nat Med - 1 week - (New C3)
No biomarker
Hepatocellular Cancer
No biomarker
Hepatocellular Cancer
bevacizumab + atezolizumab
Sensitive: A1 - Approval
Businesswire - 2 weeks (New B)
bevacizumab + atezolizumab
Sensitive
:
A1
Businesswire - 2wk
bevacizumab + atezolizumab
Sensitive: A1 - Approval
Businesswire - 2 weeks
bevacizumab + atezolizumab
Sensitive
:
A1
Businesswire - 2 weeks - (New B)
No biomarker
Hepatocellular Cancer
No biomarker
Hepatocellular Cancer
sorafenib
Sensitive: A1 - Approval
ASCO-GI 2023 - 2 weeks (New B)
sorafenib
Sensitive
:
A1
ASCO-GI 2023 - 2wk
sorafenib
Sensitive: A1 - Approval
ASCO-GI 2023 - 2 weeks
sorafenib
Sensitive
:
A1
ASCO-GI 2023 - 2 weeks - (New B)
No biomarker
Colorectal Cancer
No biomarker
Colorectal Cancer
fruquintinib
Sensitive: A1 - Approval
ASCO-GI 2023 - 2 weeks (New B)
fruquintinib
Sensitive
:
A1
ASCO-GI 2023 - 2wk
fruquintinib
Sensitive: A1 - Approval
ASCO-GI 2023 - 2 weeks
fruquintinib
Sensitive
:
A1
ASCO-GI 2023 - 2 weeks - (New B)
BRAF V600E
Colorectal Cancer
BRAF V600E
Colorectal Cancer
cetuximab + trametinib + dabrafenib
Sensitive: A2 - Guideline
ASCO-GI 2023 - 2 weeks (New C3)
cetuximab + trametinib + dabrafenib
Sensitive
:
A2
ASCO-GI 2023 - 2wk
cetuximab + trametinib + dabrafenib
Sensitive: A2 - Guideline
ASCO-GI 2023 - 2 weeks
cetuximab + trametinib + dabrafenib
Sensitive
:
A2
ASCO-GI 2023 - 2 weeks - (New C3)
PD-L1 expression
Gastric Cancer
PD-L1 expression
Gastric Cancer
tislelizumab
Sensitive: B - Late Trials
ASCO-GI 2023 - 2 weeks (New B)
tislelizumab
Sensitive
:
B
ASCO-GI 2023 - 2wk
tislelizumab
Sensitive: B - Late Trials
ASCO-GI 2023 - 2 weeks
tislelizumab
Sensitive
:
B
ASCO-GI 2023 - 2 weeks - (New B)
PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
tislelizumab
Sensitive: B - Late Trials
ASCO-GI 2023 - 2 weeks (New B)
tislelizumab
Sensitive
:
B
ASCO-GI 2023 - 2wk
tislelizumab
Sensitive: B - Late Trials
ASCO-GI 2023 - 2 weeks
tislelizumab
Sensitive
:
B
ASCO-GI 2023 - 2 weeks - (New B)
CLDN18.2 positive + HER-2 negative
Gastroesophageal Junction Adenocarcinoma
CLDN18.2 positive + HER-2 negative
Gastroesophageal Junction Adenocarcinoma
IMAB362
Sensitive: B - Late Trials
ASCO-GI 2023 - 2 weeks (New B)
IMAB362
Sensitive
:
B
ASCO-GI 2023 - 2wk
IMAB362
Sensitive: B - Late Trials
ASCO-GI 2023 - 2 weeks
IMAB362
Sensitive
:
B
ASCO-GI 2023 - 2 weeks - (New B)
CLDN18.2 positive + HER-2 negative
Gastric Cancer
CLDN18.2 positive + HER-2 negative
Gastric Cancer
IMAB362
Sensitive: B - Late Trials
ASCO-GI 2023 - 2 weeks (New B)
IMAB362
Sensitive
:
B
ASCO-GI 2023 - 2wk
IMAB362
Sensitive: B - Late Trials
ASCO-GI 2023 - 2 weeks
IMAB362
Sensitive
:
B
ASCO-GI 2023 - 2 weeks - (New B)
PD-L1 expression
Esophageal Squamous Cell Carcinoma
PD-L1 expression
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive: A1 - Approval
ASCO-GI 2023 - 2 weeks (New B)
nivolumab
Sensitive
:
A1
ASCO-GI 2023 - 2wk
nivolumab
Sensitive: A1 - Approval
ASCO-GI 2023 - 2 weeks
nivolumab
Sensitive
:
A1
ASCO-GI 2023 - 2 weeks - (New B)
MSI-H/dMMR
Colorectal Cancer
MSI-H/dMMR
Colorectal Cancer
pembrolizumab
Sensitive: A1 - Approval
ASCO-GI 2023 - 2 weeks (New C3)
pembrolizumab
Sensitive
:
A1
ASCO-GI 2023 - 2wk
pembrolizumab
Sensitive: A1 - Approval
ASCO-GI 2023 - 2 weeks
pembrolizumab
Sensitive
:
A1
ASCO-GI 2023 - 2 weeks - (New C3)
BRAF V600E
Colorectal Cancer
BRAF V600E
Colorectal Cancer
cetuximab + encorafenib
Sensitive: A1 - Approval
ASCO-GI 2023 - 2 weeks (New C3)
cetuximab + encorafenib
Sensitive
:
A1
ASCO-GI 2023 - 2wk
cetuximab + encorafenib
Sensitive: A1 - Approval
ASCO-GI 2023 - 2 weeks
cetuximab + encorafenib
Sensitive
:
A1
ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 negative + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
HER-2 negative + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
ASCO-GI 2023 - 2 weeks (New C3)
nivolumab
Sensitive
:
A1
ASCO-GI 2023 - 2wk
nivolumab
Sensitive: A1 - Approval
ASCO-GI 2023 - 2 weeks
nivolumab
Sensitive
:
A1
ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 negative + PD-L1 expression
Gastric Cancer
HER-2 negative + PD-L1 expression
Gastric Cancer
nivolumab
Sensitive: A1 - Approval
ASCO-GI 2023 - 2 weeks (New C3)
nivolumab
Sensitive
:
A1
ASCO-GI 2023 - 2wk
nivolumab
Sensitive: A1 - Approval
ASCO-GI 2023 - 2 weeks
nivolumab
Sensitive
:
A1
ASCO-GI 2023 - 2 weeks - (New C3)
FGFR2 rearrangement
Cholangiocarcinoma
FGFR2 rearrangement
Cholangiocarcinoma
futibatinib
Sensitive: A1 - Approval
N Engl J Med - 2 weeks (New C3)
futibatinib
Sensitive
:
A1
N Engl J Med - 2wk
futibatinib
Sensitive: A1 - Approval
N Engl J Med - 2 weeks
futibatinib
Sensitive
:
A1
N Engl J Med - 2 weeks - (New C3)
FGFR2 fusion
Cholangiocarcinoma
FGFR2 fusion
Cholangiocarcinoma
futibatinib
Sensitive: A1 - Approval
N Engl J Med - 2 weeks (New C3)
futibatinib
Sensitive
:
A1
N Engl J Med - 2wk
futibatinib
Sensitive: A1 - Approval
N Engl J Med - 2 weeks
futibatinib
Sensitive
:
A1
N Engl J Med - 2 weeks - (New C3)
HER-2 negative + PD-L1 expression
Esophageal Adenocarcinoma
HER-2 negative + PD-L1 expression
Esophageal Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
ASCO-GI 2023 - 2 weeks (New C3)
nivolumab
Sensitive
:
A1
ASCO-GI 2023 - 2wk
nivolumab
Sensitive: A1 - Approval
ASCO-GI 2023 - 2 weeks
nivolumab
Sensitive
:
A1
ASCO-GI 2023 - 2 weeks - (New C3)
PD-L1 expression
Esophageal Squamous Cell Carcinoma
PD-L1 expression
Esophageal Squamous Cell Carcinoma
nivolumab + ipilimumab
Sensitive: A1 - Approval
ASCO-GI 2023 - 2 weeks (New B)
nivolumab + ipilimumab
Sensitive
:
A1
ASCO-GI 2023 - 2wk
nivolumab + ipilimumab
Sensitive: A1 - Approval
ASCO-GI 2023 - 2 weeks
nivolumab + ipilimumab
Sensitive
:
A1
ASCO-GI 2023 - 2 weeks - (New B)
RAS wild-type + HER-2 positive
Colorectal Cancer
RAS wild-type + HER-2 positive
Colorectal Cancer
trastuzumab + tucatinib
Sensitive: A1 - Approval
FDA - 2 weeks (New A1)
trastuzumab + tucatinib
Sensitive
:
A1
FDA - 2wk
trastuzumab + tucatinib
Sensitive: A1 - Approval
FDA - 2 weeks
trastuzumab + tucatinib
Sensitive
:
A1
FDA - 2 weeks - (New A1)
PD-L1 expression
Biliary Tract Cancer
PD-L1 expression
Biliary Tract Cancer
nivolumab
Sensitive: C1 - Off-label
ASCO-GI 2023 - 2 weeks (New C3)
nivolumab
Sensitive
:
C1
ASCO-GI 2023 - 2wk
nivolumab
Sensitive: C1 - Off-label
ASCO-GI 2023 - 2 weeks
nivolumab
Sensitive
:
C1
ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 positive
Gastric Cancer
HER-2 positive
Gastric Cancer
pyrotinib + dalpiciclib
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
pyrotinib + dalpiciclib
Sensitive
:
C2
ASCO-GI 2023 - 2wk
pyrotinib + dalpiciclib
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
pyrotinib + dalpiciclib
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR
Colorectal Cancer
MSI-H/dMMR
Colorectal Cancer
regorafenib
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
regorafenib
Sensitive
:
C2
ASCO-GI 2023 - 2wk
regorafenib
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
regorafenib
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
camrelizumab + rivoceranib
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
camrelizumab + rivoceranib
Sensitive
:
C2
ASCO-GI 2023 - 2wk
camrelizumab + rivoceranib
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
camrelizumab + rivoceranib
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 negative
Gastric Cancer
HER-2 negative
Gastric Cancer
camrelizumab + rivoceranib
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
camrelizumab + rivoceranib
Sensitive
:
C2
ASCO-GI 2023 - 2wk
camrelizumab + rivoceranib
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
camrelizumab + rivoceranib
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
Her-VAXX
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
Her-VAXX
Sensitive
:
C2
ASCO-GI 2023 - 2wk
Her-VAXX
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
Her-VAXX
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
FGFR2 fusion
Cholangiocarcinoma
FGFR2 fusion
Cholangiocarcinoma
ICP-192
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
ICP-192
Sensitive
:
C2
ASCO-GI 2023 - 2wk
ICP-192
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
ICP-192
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
FGFR2 mutation
Cholangiocarcinoma
FGFR2 mutation
Cholangiocarcinoma
TT-00420
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
TT-00420
Sensitive
:
C2
ASCO-GI 2023 - 2wk
TT-00420
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
TT-00420
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
KRAS wild-type
Colorectal Cancer
KRAS wild-type
Colorectal Cancer
cetuximab
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
cetuximab
Sensitive
:
C2
ASCO-GI 2023 - 2wk
cetuximab
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
cetuximab
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
KRAS wild-type
Colorectal Cancer
KRAS wild-type
Colorectal Cancer
bevacizumab
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
bevacizumab
Sensitive
:
C2
ASCO-GI 2023 - 2wk
bevacizumab
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
bevacizumab
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
BRAF wild-type
Colorectal Cancer
BRAF wild-type
Colorectal Cancer
anlotinib
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
anlotinib
Sensitive
:
C2
ASCO-GI 2023 - 2wk
anlotinib
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
anlotinib
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 overexpression
Gastric Cancer
HER-2 overexpression
Gastric Cancer
Her-VAXX
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
Her-VAXX
Sensitive
:
C2
ASCO-GI 2023 - 2wk
Her-VAXX
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
Her-VAXX
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR
Gastric Cancer
MSI-H/dMMR
Gastric Cancer
durvalumab + tremelimumab
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
durvalumab + tremelimumab
Sensitive
:
C2
ASCO-GI 2023 - 2wk
durvalumab + tremelimumab
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
durvalumab + tremelimumab
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
CLDN18.2 positive
Gastric Cancer
CLDN18.2 positive
Gastric Cancer
AB011
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
AB011
Sensitive
:
C2
ASCO-GI 2023 - 2wk
AB011
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
AB011
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
CLDN18.2 positive
Gastroesophageal Junction Adenocarcinoma
CLDN18.2 positive
Gastroesophageal Junction Adenocarcinoma
CMG901
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
CMG901
Sensitive
:
C2
ASCO-GI 2023 - 2wk
CMG901
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
CMG901
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
CLDN18.2 positive
Gastric Cancer
CLDN18.2 positive
Gastric Cancer
CMG901
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
CMG901
Sensitive
:
C2
ASCO-GI 2023 - 2wk
CMG901
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
CMG901
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
MDM2 amplification
Cholangiocarcinoma
MDM2 amplification
Cholangiocarcinoma
BI 907828
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
BI 907828
Sensitive
:
C2
ASCO-GI 2023 - 2wk
BI 907828
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
BI 907828
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
MDM2 amplification
Biliary Tract Cancer
MDM2 amplification
Biliary Tract Cancer
BI 907828
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
BI 907828
Sensitive
:
C2
ASCO-GI 2023 - 2wk
BI 907828
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
BI 907828
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
FGFR2 fusion
Cholangiocarcinoma
FGFR2 fusion
Cholangiocarcinoma
TT-00420
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
TT-00420
Sensitive
:
C2
ASCO-GI 2023 - 2wk
TT-00420
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
TT-00420
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR
Colorectal Cancer
MSI-H/dMMR
Colorectal Cancer
Immunotherapy
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
Immunotherapy
Sensitive
:
C3
ASCO-GI 2023 - 2wk
Immunotherapy
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
Immunotherapy
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 expression
Gastroesophageal Cancer
HER-2 expression
Gastroesophageal Cancer
ZW25
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
ZW25
Sensitive
:
C3
ASCO-GI 2023 - 2wk
ZW25
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
ZW25
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
EREG overexpression + AREG overexpression
Colorectal Cancer
EREG overexpression + AREG overexpression
Colorectal Cancer
panitumumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
panitumumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
panitumumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
panitumumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
BRAF V600E
Colorectal Cancer
BRAF V600E
Colorectal Cancer
erlotinib + vemurafenib
Sensitive: C3 – Early Trials
Clin Cancer Res - 2 weeks (New C3)
erlotinib + vemurafenib
Sensitive
:
C3
Clin Cancer Res - 2wk
erlotinib + vemurafenib
Sensitive: C3 – Early Trials
Clin Cancer Res - 2 weeks
erlotinib + vemurafenib
Sensitive
:
C3
Clin Cancer Res - 2 weeks - (New C3)
RAS wild-type
Colorectal Cancer
RAS wild-type
Colorectal Cancer
anlotinib
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
anlotinib
Sensitive
:
C3
ASCO-GI 2023 - 2wk
anlotinib
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
anlotinib
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
RAS wild-type
Colorectal Cancer
RAS wild-type
Colorectal Cancer
cetuximab + tislelizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
cetuximab + tislelizumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
cetuximab + tislelizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
cetuximab + tislelizumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
BRAF wild-type + HER-2 positive
Colorectal Cancer
BRAF wild-type + HER-2 positive
Colorectal Cancer
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
trastuzumab + pertuzumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
trastuzumab + pertuzumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
RAS wild-type + HER-2 positive
Colorectal Cancer
RAS wild-type + HER-2 positive
Colorectal Cancer
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
trastuzumab + pertuzumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
trastuzumab + pertuzumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR
Gastroesophageal Junction Adenocarcinoma
MSI-H/dMMR
Gastroesophageal Junction Adenocarcinoma
durvalumab + tremelimumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
durvalumab + tremelimumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
durvalumab + tremelimumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
durvalumab + tremelimumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
CLDN18.2 positive
Gastroesophageal Junction Adenocarcinoma
CLDN18.2 positive
Gastroesophageal Junction Adenocarcinoma
AB011
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
AB011
Sensitive
:
C3
ASCO-GI 2023 - 2wk
AB011
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
AB011
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
TMB-H
Gastric Cancer
TMB-H
Gastric Cancer
durvalumab + tremelimumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
durvalumab + tremelimumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
durvalumab + tremelimumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
durvalumab + tremelimumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
camrelizumab + pyrotinib
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
camrelizumab + pyrotinib
Sensitive
:
C3
ASCO-GI 2023 - 2wk
camrelizumab + pyrotinib
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
camrelizumab + pyrotinib
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 positive
Gastric Cancer
HER-2 positive
Gastric Cancer
camrelizumab + pyrotinib
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
camrelizumab + pyrotinib
Sensitive
:
C3
ASCO-GI 2023 - 2wk
camrelizumab + pyrotinib
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
camrelizumab + pyrotinib
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
anlotinib + APL-502
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
anlotinib + APL-502
Sensitive
:
C3
ASCO-GI 2023 - 2wk
anlotinib + APL-502
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
anlotinib + APL-502
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 negative
Gastric Cancer
HER-2 negative
Gastric Cancer
anlotinib + APL-502
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
anlotinib + APL-502
Sensitive
:
C3
ASCO-GI 2023 - 2wk
anlotinib + APL-502
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
anlotinib + APL-502
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
FGFR fusion
Cholangiocarcinoma
FGFR fusion
Cholangiocarcinoma
erdafitinib
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
erdafitinib
Sensitive
:
C3
ASCO-GI 2023 - 2wk
erdafitinib
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
erdafitinib
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
FGFR mutation
Cholangiocarcinoma
FGFR mutation
Cholangiocarcinoma
erdafitinib
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
erdafitinib
Sensitive
:
C3
ASCO-GI 2023 - 2wk
erdafitinib
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
erdafitinib
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MUC16 elevation
Colorectal Cancer
MUC16 elevation
Colorectal Cancer
regorafenib
Resistant: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
regorafenib
Resistant
:
C3
ASCO-GI 2023 - 2wk
regorafenib
Resistant: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
regorafenib
Resistant
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MUC16 elevation
Colorectal Cancer
MUC16 elevation
Colorectal Cancer
trifluridine/tipiracil
Resistant: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
trifluridine / tipiracil
Resistant
:
C3
ASCO-GI 2023 - 2wk
trifluridine/tipiracil
Resistant: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
trifluridine / tipiracil
Resistant
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 positive
Gastric Cancer
HER-2 positive
Gastric Cancer
olaparib + durvalumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
olaparib + durvalumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
olaparib + durvalumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
olaparib + durvalumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
PD-L1 expression
Gastric Cancer
PD-L1 expression
Gastric Cancer
paclitaxel + minnelide
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
paclitaxel + minnelide
Sensitive
:
C3
ASCO-GI 2023 - 2wk
paclitaxel + minnelide
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
paclitaxel + minnelide
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 positive
Gastric Cancer
HER-2 positive
Gastric Cancer
paclitaxel + minnelide
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
paclitaxel + minnelide
Sensitive
:
C3
ASCO-GI 2023 - 2wk
paclitaxel + minnelide
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
paclitaxel + minnelide
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
CAPRIN-1 expression
Gastroesophageal Junction Adenocarcinoma
CAPRIN-1 expression
Gastroesophageal Junction Adenocarcinoma
ramucirumab + TRK-950
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
ramucirumab + TRK-950
Sensitive
:
C3
ASCO-GI 2023 - 2wk
ramucirumab + TRK-950
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
ramucirumab + TRK-950
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
CAPRIN-1 expression
Gastric Cancer
CAPRIN-1 expression
Gastric Cancer
ramucirumab + TRK-950
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
ramucirumab + TRK-950
Sensitive
:
C3
ASCO-GI 2023 - 2wk
ramucirumab + TRK-950
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
ramucirumab + TRK-950
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
CEACAM5 underexpression + MSI-H/dMMR
Colorectal Cancer
CEACAM5 underexpression + MSI-H/dMMR
Colorectal Cancer
nivolumab + ipilimumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
nivolumab + ipilimumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
nivolumab + ipilimumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
nivolumab + ipilimumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
CEACAM5 underexpression + MSI-H/dMMR
Colorectal Cancer
CEACAM5 underexpression + MSI-H/dMMR
Colorectal Cancer
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
THBS2-L
Colorectal Cancer
THBS2-L
Colorectal Cancer
ramucirumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
ramucirumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
ramucirumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
ramucirumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + CD74 overexpression
Colorectal Cancer
MSI-H/dMMR + CD74 overexpression
Colorectal Cancer
nivolumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
nivolumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
nivolumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
nivolumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DQA1 overexpression
Colorectal Cancer
MSI-H/dMMR + HLA-DQA1 overexpression
Colorectal Cancer
nivolumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
nivolumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
nivolumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
nivolumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DPA1 overexpression
Colorectal Cancer
MSI-H/dMMR + HLA-DPA1 overexpression
Colorectal Cancer
nivolumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
nivolumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
nivolumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
nivolumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DQB1 overexpression
Colorectal Cancer
MSI-H/dMMR + HLA-DQB1 overexpression
Colorectal Cancer
nivolumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
nivolumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
nivolumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
nivolumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-B overexpression
Colorectal Cancer
MSI-H/dMMR + HLA-B overexpression
Colorectal Cancer
nivolumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
nivolumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
nivolumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
nivolumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DRB1 overexpression
Colorectal Cancer
MSI-H/dMMR + HLA-DRB1 overexpression
Colorectal Cancer
nivolumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
nivolumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
nivolumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
nivolumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DQA1 overexpression
Colorectal Cancer
MSI-H/dMMR + HLA-DQA1 overexpression
Colorectal Cancer
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + CD74 overexpression
Colorectal Cancer
MSI-H/dMMR + CD74 overexpression
Colorectal Cancer
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DPA1 overexpression
Colorectal Cancer
MSI-H/dMMR + HLA-DPA1 overexpression
Colorectal Cancer
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DQB1 overexpression
Colorectal Cancer
MSI-H/dMMR + HLA-DQB1 overexpression
Colorectal Cancer
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-B overexpression
Colorectal Cancer
MSI-H/dMMR + HLA-B overexpression
Colorectal Cancer
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DRB1 overexpression
Colorectal Cancer
MSI-H/dMMR + HLA-DRB1 overexpression
Colorectal Cancer
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
EREG overexpression + AREG overexpression
Colorectal Cancer
EREG overexpression + AREG overexpression
Colorectal Cancer
cetuximab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
cetuximab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
cetuximab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
cetuximab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
FGFR2 rearrangement
Cholangiocarcinoma
FGFR2 rearrangement
Cholangiocarcinoma
ICP-192
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
ICP-192
Sensitive
:
C3
ASCO-GI 2023 - 2wk
ICP-192
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
ICP-192
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MDM2 amplification
Ampulla of Vater Carcinoma
MDM2 amplification
Ampulla of Vater Carcinoma
BI 907828
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
BI 907828
Sensitive
:
C3
ASCO-GI 2023 - 2wk
BI 907828
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
BI 907828
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
KRAS mutation
Biliary Tract Cancer
KRAS mutation
Biliary Tract Cancer
trastuzumab + pertuzumab
Resistant: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
trastuzumab + pertuzumab
Resistant
:
C3
ASCO-GI 2023 - 2wk
trastuzumab + pertuzumab
Resistant: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
trastuzumab + pertuzumab
Resistant
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
ERBB3 mutation + HER-2 amplification
Biliary Tract Cancer
ERBB3 mutation + HER-2 amplification
Biliary Tract Cancer
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
trastuzumab + pertuzumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
trastuzumab + pertuzumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 mutation
Biliary Tract Cancer
HER-2 mutation
Biliary Tract Cancer
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
trastuzumab + pertuzumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
trastuzumab + pertuzumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 amplification
Biliary Tract Cancer
HER-2 amplification
Biliary Tract Cancer
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
trastuzumab + pertuzumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
trastuzumab + pertuzumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
KRAS G12R
Pancreatic Ductal Adenocarcinoma
KRAS G12R
Pancreatic Ductal Adenocarcinoma
FOLFIRINOX
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
FOLFIRINOX
Sensitive
:
C3
ASCO-GI 2023 - 2wk
FOLFIRINOX
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
FOLFIRINOX
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
KRAS G12R
Pancreatic Ductal Adenocarcinoma
KRAS G12R
Pancreatic Ductal Adenocarcinoma
paclitaxel + gemcitabine
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
paclitaxel + gemcitabine
Sensitive
:
C3
ASCO-GI 2023 - 2wk
paclitaxel + gemcitabine
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
paclitaxel + gemcitabine
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
ATM mutation
Pancreatic Ductal Adenocarcinoma
ATM mutation
Pancreatic Ductal Adenocarcinoma
irinotecan
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
irinotecan
Sensitive
:
C3
ASCO-GI 2023 - 2wk
irinotecan
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
irinotecan
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
CHEK2 mutation
Pancreatic Ductal Adenocarcinoma
CHEK2 mutation
Pancreatic Ductal Adenocarcinoma
irinotecan
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
irinotecan
Sensitive
:
C3
ASCO-GI 2023 - 2wk
irinotecan
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
irinotecan
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
FGFR2 rearrangement
Cholangiocarcinoma
FGFR2 rearrangement
Cholangiocarcinoma
TT-00420
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
TT-00420
Sensitive
:
C3
ASCO-GI 2023 - 2wk
TT-00420
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
TT-00420
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + RAS mutation
Colorectal Cancer
MSI-H/dMMR + RAS mutation
Colorectal Cancer
Immunotherapy
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
Immunotherapy
Sensitive
:
C3
ASCO-GI 2023 - 2wk
Immunotherapy
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
Immunotherapy
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
PD-L1 expression
Colorectal Cancer
PD-L1 expression
Colorectal Cancer
AGEN2034 + AGEN1181
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
AGEN2034 + AGEN1181
Sensitive
:
C3
ASCO-GI 2023 - 2wk
AGEN2034 + AGEN1181
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
AGEN2034 + AGEN1181
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
NRAS mutation
Colorectal Cancer
NRAS mutation
Colorectal Cancer
AGEN2034 + AGEN1181
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
AGEN2034 + AGEN1181
Sensitive
:
C3
ASCO-GI 2023 - 2wk
AGEN2034 + AGEN1181
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
AGEN2034 + AGEN1181
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
KRAS mutation
Colorectal Cancer
KRAS mutation
Colorectal Cancer
AGEN2034 + AGEN1181
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
AGEN2034 + AGEN1181
Sensitive
:
C3
ASCO-GI 2023 - 2wk
AGEN2034 + AGEN1181
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
AGEN2034 + AGEN1181
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
BAP1 mutation + IDH2 R172W + CDKN2A deletion + CDKN2B deletion
Cholangiocarcinoma
BAP1 mutation + IDH2 R172W + CDKN2A deletion + CDKN2B deletion
Cholangiocarcinoma
palbociclib
Sensitive: C4 – Case Studies
Onco Targets Ther - 2 weeks (New C4)
palbociclib
Sensitive
:
C4
Onco Targets Ther - 2wk
palbociclib
Sensitive: C4 – Case Studies
Onco Targets Ther - 2 weeks
palbociclib
Sensitive
:
C4
Onco Targets Ther - 2 weeks - (New C4)
CAPZA2-MET fusion + MET amplification
Cholangiocarcinoma
CAPZA2-MET fusion + MET amplification
Cholangiocarcinoma
capmatinib
Sensitive: C4 – Case Studies
The Oncologist - 2 weeks (New C4)
capmatinib
Sensitive
:
C4
The Oncologist - 2wk
capmatinib
Sensitive: C4 – Case Studies
The Oncologist - 2 weeks
capmatinib
Sensitive
:
C4
The Oncologist - 2 weeks - (New C4)
PIK3CA mutation
Colorectal Cancer
PIK3CA mutation
Colorectal Cancer
alpelisib + ribociclib
Sensitive: D – Preclinical
ASCO-GI 2023 - 2 weeks (New D)
alpelisib + ribociclib
Sensitive
:
D
ASCO-GI 2023 - 2wk
alpelisib + ribociclib
Sensitive: D – Preclinical
ASCO-GI 2023 - 2 weeks
alpelisib + ribociclib
Sensitive
:
D
ASCO-GI 2023 - 2 weeks - (New D)
KRAS mutation
Colorectal Cancer
KRAS mutation
Colorectal Cancer
alpelisib + ribociclib
Sensitive: D – Preclinical
ASCO-GI 2023 - 2 weeks (New D)
alpelisib + ribociclib
Sensitive
:
D
ASCO-GI 2023 - 2wk
alpelisib + ribociclib
Sensitive: D – Preclinical
ASCO-GI 2023 - 2 weeks
alpelisib + ribociclib
Sensitive
:
D
ASCO-GI 2023 - 2 weeks - (New D)
MSI-H/dMMR + HLA-DPB1 overexpression
Colorectal Cancer
MSI-H/dMMR + HLA-DPB1 overexpression
Colorectal Cancer
nivolumab
Sensitive: D – Preclinical
ASCO-GI 2023 - 2 weeks (New D)
nivolumab
Sensitive
:
D
ASCO-GI 2023 - 2wk
nivolumab
Sensitive: D – Preclinical
ASCO-GI 2023 - 2 weeks
nivolumab
Sensitive
:
D
ASCO-GI 2023 - 2 weeks - (New D)
MSI-H/dMMR + HLA-DPB1 overexpression
Colorectal Cancer
MSI-H/dMMR + HLA-DPB1 overexpression
Colorectal Cancer
pembrolizumab
Sensitive: D – Preclinical
ASCO-GI 2023 - 2 weeks (New D)
pembrolizumab
Sensitive
:
D
ASCO-GI 2023 - 2wk
pembrolizumab
Sensitive: D – Preclinical
ASCO-GI 2023 - 2 weeks
pembrolizumab
Sensitive
:
D
ASCO-GI 2023 - 2 weeks - (New D)
PIK3CA mutation + KRAS mutation
Colorectal Cancer
PIK3CA mutation + KRAS mutation
Colorectal Cancer
alpelisib + ribociclib
Sensitive: D – Preclinical
ASCO-GI 2023 - 2 weeks (New D)
alpelisib + ribociclib
Sensitive
:
D
ASCO-GI 2023 - 2wk
alpelisib + ribociclib
Sensitive: D – Preclinical
ASCO-GI 2023 - 2 weeks
alpelisib + ribociclib
Sensitive
:
D
ASCO-GI 2023 - 2 weeks - (New D)
PIK3CA wild-type + KRAS wild-type
Colorectal Cancer
PIK3CA wild-type + KRAS wild-type
Colorectal Cancer
alpelisib + ribociclib
Sensitive: D – Preclinical
ASCO-GI 2023 - 2 weeks (New D)
alpelisib + ribociclib
Sensitive
:
D
ASCO-GI 2023 - 2wk
alpelisib + ribociclib
Sensitive: D – Preclinical
ASCO-GI 2023 - 2 weeks
alpelisib + ribociclib
Sensitive
:
D
ASCO-GI 2023 - 2 weeks - (New D)
MSI-H/dMMR
Small Intestinal Carcinoma
MSI-H/dMMR
Small Intestinal Carcinoma
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Sensitive: A1 - Approval
trastuzumab
Sensitive
:
A1
trastuzumab
Sensitive: A1 - Approval
trastuzumab
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Esophageal Cancer
No biomarker
Esophageal Cancer
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Esophageal Squamous Cell Carcinoma
No biomarker
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Esophageal Adenocarcinoma
No biomarker
Esophageal Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Gastric Cancer
No biomarker
Gastric Cancer
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Gastric Adenocarcinoma
No biomarker
Gastric Adenocarcinoma
cisplatin + docetaxel + 5-fluorouracil
Sensitive: A1 - Approval
cisplatin + docetaxel + 5-fluorouracil
Sensitive
:
A1
cisplatin + docetaxel + 5-fluorouracil
Sensitive: A1 - Approval
cisplatin + docetaxel + 5-fluorouracil
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
cisplatin + docetaxel + 5-fluorouracil
Sensitive: A1 - Approval
cisplatin + docetaxel + 5-fluorouracil
Sensitive
:
A1
cisplatin + docetaxel + 5-fluorouracil
Sensitive: A1 - Approval
cisplatin + docetaxel + 5-fluorouracil
Sensitive
:
A1
HER-2 positive
Gastric Cancer
HER-2 positive
Gastric Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
BRCA2 mutation
Pancreatic Cancer
BRCA2 mutation
Pancreatic Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
No biomarker
Hepatocellular Cancer
No biomarker
Hepatocellular Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
BRCA1 mutation
Pancreatic Cancer
BRCA1 mutation
Pancreatic Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
FGFR2 rearrangement
Cholangiocarcinoma
FGFR2 rearrangement
Cholangiocarcinoma
infigratinib
Sensitive: A1 - Approval
infigratinib
Sensitive
:
A1
infigratinib
Sensitive: A1 - Approval
infigratinib
Sensitive
:
A1
FGFR2 fusion
Cholangiocarcinoma
FGFR2 fusion
Cholangiocarcinoma
infigratinib
Sensitive: A1 - Approval
infigratinib
Sensitive
:
A1
infigratinib
Sensitive: A1 - Approval
infigratinib
Sensitive
:
A1
IDH1 mutation
Cholangiocarcinoma
IDH1 mutation
Cholangiocarcinoma
ivosidenib
Sensitive: A1 - Approval
ivosidenib
Sensitive
:
A1
ivosidenib
Sensitive: A1 - Approval
ivosidenib
Sensitive
:
A1
MSI-H/dMMR
Colorectal Cancer
MSI-H/dMMR
Colorectal Cancer
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
No biomarker
Gastric Cancer
No biomarker
Gastric Cancer
TPF
Sensitive: A1 - Approval
TPF
Sensitive
:
A1
TPF
Sensitive: A1 - Approval
TPF
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
TPF
Sensitive: A1 - Approval
TPF
Sensitive
:
A1
TPF
Sensitive: A1 - Approval
TPF
Sensitive
:
A1
HER-2 positive
Gastric Cancer
HER-2 positive
Gastric Cancer
pembrolizumab + trastuzumab
Sensitive: A1 - Approval
pembrolizumab + trastuzumab
Sensitive
:
A1
pembrolizumab + trastuzumab
Sensitive: A1 - Approval
pembrolizumab + trastuzumab
Sensitive
:
A1
BRAF V600E
Colorectal Cancer
BRAF V600E
Colorectal Cancer
cetuximab + encorafenib + binimetinib
Sensitive: A1 - Approval
cetuximab + encorafenib + binimetinib
Sensitive
:
A1
cetuximab + encorafenib + binimetinib
Sensitive: A1 - Approval
cetuximab + encorafenib + binimetinib
Sensitive
:
A1
No biomarker
Colon Cancer
No biomarker
Colon Cancer
capecitabine
Sensitive: A1 - Approval
capecitabine
Sensitive
:
A1
capecitabine
Sensitive: A1 - Approval
capecitabine
Sensitive
:
A1
No biomarker
Rectal Cancer
No biomarker
Rectal Cancer
FOLFIRI
Sensitive: A1 - Approval
FOLFIRI
Sensitive
:
A1
FOLFIRI
Sensitive: A1 - Approval
FOLFIRI
Sensitive
:
A1
No biomarker
Colon Cancer
No biomarker
Colon Cancer
5-fluorouracil + irinotecan
Sensitive: A1 - Approval
5-fluorouracil + irinotecan
Sensitive
:
A1
5-fluorouracil + irinotecan
Sensitive: A1 - Approval
5-fluorouracil + irinotecan
Sensitive
:
A1
PD-L1 expression
Esophageal Squamous Cell Carcinoma
PD-L1 expression
Esophageal Squamous Cell Carcinoma
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
No biomarker
Colorectal Cancer
No biomarker
Colorectal Cancer
bevacizumab
Sensitive: A1 - Approval
bevacizumab
Sensitive
:
A1
bevacizumab
Sensitive: A1 - Approval
bevacizumab
Sensitive
:
A1
HER-2 overexpression
Gastric Cancer
HER-2 overexpression
Gastric Cancer
trastuzumab
Sensitive: A1 - Approval
trastuzumab
Sensitive
:
A1
trastuzumab
Sensitive: A1 - Approval
trastuzumab
Sensitive
:
A1
No biomarker
Esophageal Cancer
No biomarker
Esophageal Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
HER-2 overexpression
Gastric Cancer
HER-2 overexpression
Gastric Cancer
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login